tbuckley/cabot-search huggingface dataset:
P2.06-23 The Accuracy of Video-Assisted Thoracic Surgery Pleural Biopsy in Patients with Suspected Malignant Pleural Mesothelioma: A Real-Life Study
Authors: F. Guerrera, E. Migliore, P. Lausi, L. Delsedime, L. Costardi, D. Di Cuonzo, P. Lyberis, P.L. Filosso, M. Papotti, E. Ruffini, D. Mirabelli
Journal: Journal of Thoracic Oncology (2019)
P1.01-118 Overall Survival in Pts with EGFRm+ NSCLC Receiving Sequential Afatinib and Osimertinib: Updated Analysis of the GioTag Study
Authors: M.J. Hochmair, A. Morabito, D. Hao, C. Yang, R. Soo, J. Yang, R. Gucalp, B. Halmos, L. Wang, A. Märten, T. Cufer
Journal: Journal of Thoracic Oncology (2019)
Association of Widespread Adoption of the 39-Week Rule With Overall Mortality Due to Stillbirth and Infant Death
Authors: Rachel A. Pilliod, Mekhala Dissanayake, Yvonne W. Cheng, Aaron B. Caughey
Journal: JAMA Pediatrics (2019)

To improve neonatal morbidity, efforts have been made to reduce elective deliveries prior to 39 weeks' gestation, also known as the 39-week rule. Prolonging pregnancies also prolongs exposure to the risk of stillbirth. The true association of a 39-week rule with mortality is unknown and studies to date have shown conflicting results.To determine if widespread adoption of a 39-week rule, limiting elective deliveries prior to 39 weeks' gestation, is associated with an increase or decrease in overall mortality when considering both stillbirths and infant deaths.This historical cohort study used birth certificate and infant death certificate data in the United States to compare years before and after the adoption of the 39-week rule. Births between 2008 and 2009 were considered to be in the preadoption period (n = 7 322 234), and those between 2011 and 2012 were considered to be in the postadoption period (n = 6 972 626). Included births were singleton, nonanomalous births between 37 0/7 weeks' and 42 6/7 weeks' gestation. Statistical analysis was performed from July 19, 2016, through June 27, 2019.The exposure of interest was the Joint Commission adoption of the 39-week rule as a quality measure.The primary outcomes of interest were stillbirth and infant death.A total of 7 322 234 births (49.0% girls and 51.0% boys) were included in the preadoption period and 6 972 626 births (49.1% girls and 50.9% boys) were included in the postadoption period. Compared with the preadoption period, there was a decrease in the proportion of deliveries at 37 weeks (-0.06%) and 38 weeks (-2.5%) and an increase in the proportion of deliveries at 39 weeks (6.8%) and 40 weeks (0.2%) in the postadoption period (P < .001). The stillbirth rate increased in the postadoption cohort compared with preadoption (0.09% vs 0.10%; P < .001). The infant death rate decreased in the postadoption period compared with preadoption (0.21% vs 0.20%; P < .001). An overall mortality rate of 0.31% was calculated for the preadoption period and 0.30% for the postadoption period (P = .06). Additional analysis in a counterfactual model suggests that up to 34.2% of the difference in mortality could be associated with the 39-week rule.Stable overall perinatal mortality rates were observed in the 2-year period immediately after adoption of the 39-week rule, despite an increase in stillbirth.
EP1.11-01 Lung Cancer Screening and Canada’s Inuit: A Missed Opportunity
Authors: C. Bornais, C. Roberts, P. Wheatley-Price, T. Asmis, C. Dennie, D. Maziak, G. Nicholas, G. Barton, E. Alie, T. Greene
Journal: Journal of Thoracic Oncology (2019)
P2.11-25 Pre- and Post-Surgery Metabolomic Profiles in Early-Stage NSCLC Patients
Authors: W. Laosuangkoon, S. Oranratnachai, N. Paiyabhroma, L. Chailurkit, D. Munthum, N. Trachu, P. Sanvarinda, B. Ongphiphadhanakul, T. Reungwetwattana
Journal: Journal of Thoracic Oncology (2019)
P2.01-61 Multiple Primary Carcinomas (MPC) in Patients with Non Small Cell Lung Cancer (NSCLC)
Authors: M. Vaslamatzis, N. Alevizopoulos, T. Tegos, M. Pavlakis, K. Karagiorgou, C. Zoumblios, K. Gioti, V. Nikolaidou, H. Kyriazidou, E. Balis, K. Athanasiadou
Journal: Journal of Thoracic Oncology (2019)
Corrigendum to “Nanoformulated ABT-199 to effectively target Bcl-2 at mitochondrial membrane alleviates airway inflammation by inducing apoptosis” [Biomaterials 192 (2019) 429–439]
Authors: Bao-ping Tian, Fangyuan Li, Ruiqing Li, Xi Hu, Tian-wen Lai, Jingxiong Lu, Yun Zhao, Yang Du, Zeyu Liang, Chen Zhu, Wei Shao, Wen Li, Zhi-hua Chen, Xiaolian Sun, Xiaoyuan Chen, Songmin Ying, Daishun Ling, Huahao Shen
Journal: Biomaterials (2019)
International Consensus and External Validity in Global Surgery Research and Task Shifting
Authors: Rahul M. Jindal
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
P1.04-78 Efficacy of Checkpoint Inhibitors in Combination with Chemotherapy for First-Line Treatment of Advanced Non-Squamous NSCLC
Authors: K. Thein, N. Jahan, A. Sultan, S. Swarup, A. Tun, R. Yendala, S. Ball, P. Hlaing, T. Htut, S. Rehman, N. D’Cunha, F. Hardwicke, L. Tijani, S. Awasthi
Journal: Journal of Thoracic Oncology (2019)
MA23.06 Development of a Novel Genetically Engineered Mouse Model of Malignant Pleural Mesothelioma
Authors: K. Gyuraszova, T. Monteverde, T. Chernova, R. Duffin, K. Blyth, A. Berns, M. Macfarlane, D. Murphy
Journal: Journal of Thoracic Oncology (2019)
OA15.05 BIOLUMA: A Phase II Trial of Nivolumab and Ipilimumab in Lung Cancer – Prospective Evaluation of TMB in SCLC Patients
Authors: R. Fischer, J. George, A. Scheel, H. Schlösser, M. Vehreschild, D. Abdulla, S. Koleczko, S. Michels, L. Nogova, R. Riedel, M. Scheffler, L. Maas, P. Brossart, W. Engel-Riedel, F. Griesinger, C. Grohé, J. Kern, B. Hermes, K. Nachtkamp, J. Panse, M. Sebastian, M. Lehmann, R. Wiewrodt, R. Buettner, R. Thomas, J. Wolf
Journal: Journal of Thoracic Oncology (2019)
OA08.02 A Multidisciplinary Multi-Omics Study of Spatial and Temporal Tumor Evolution in Thoracic Cancers with Clinical Implications
Authors: N. Alcala, L. Mangiante, A. Poret, A. Gabriel, J. Derks, L. Moonen, S. Boyault, N. Le Stang, A. Ghantous, S. Tabone-Eglinger, F. Damiola, J. Blay, J. Mckay, A.M. Dingemans, E. Speel, C. Caux, N. Girard, S. Lantuejoul, T. Dayton, F. Galateau Sallé, L. Fernandez-Cuesta, M. Foll
Journal: Journal of Thoracic Oncology (2019)
MA23.10 Low Number of Mutations and Frequent Co-Deletions of CDKN2A and IFN Type I Characterize Malignant Pleural Mesothelioma
Authors: A. Nastase, A. Mandal, S.K. Lu, S. Gennatas, H. Anbunathan, M. Edwards, D. Morris-Rosendahl, A. Newman Taylor, R.C. Rintoul, E. Lim, S. Popat, A. Nicholson, M. Lathrop, A. Bowcock, M. Moffatt, W. Cookson
Journal: Journal of Thoracic Oncology (2019)
MA14.06 Nintedanib-Docetaxel in 2nd Line Treatment in No Squamous Non-Small Cell Lung Cancer Patients, Refractory to First Line Treatment (GFPC02-15)
Authors: J.B. Auliac, I. Monnet, A. Bizieux, L. Greillier, L. Falchero, G. Robinet, R. Lamy, P. Hauss, F. Guisier, H. Lena, C. Chouaid, A. Vergnenegre
Journal: Journal of Thoracic Oncology (2019)
P1.01-85 Treatment for Advanced NSCLC with EGFR Mutations and De Novo MET Amplification/Overexpression
Authors: H. Wang, W. Li, Q. Deng, J. Kang, H. Chen, Z. Wang, Q. Zhou, C. Xu, X. Zhang, J. Su, H. Yan, Y. Wu, J. Yang
Journal: Journal of Thoracic Oncology (2019)
P2.13-04 Molecular Nodal Restaging Based on Embryonic Markers Expression Adds No Relevant Clinical Information in Resected Lung Cancer
Authors: I. Macia, G. Aiza, R. Ramos, F. Rivas, A. Ureña, S. Aso, G. Rosado, P. Rodriguez-Taboada, C. Deniz, E. Nadal, I. Escobar, G. Capella
Journal: Journal of Thoracic Oncology (2019)
P2.04-81 Non-Small Cell Lung Cancer Treated with Immunotherapy: Multi-Institutional Experience from Argentina
Authors: M. Rizzo, M. Bluthgen, G. Recondo, M. Naveira, A. Perfetti, M. Rizzi, M. Cerini, A. Kuzminin, M. Faura, C. Silva, L. Lupinacci, N. Minatta
Journal: Journal of Thoracic Oncology (2019)
EP1.03-35 Prevalence, Clinicopathologic Characteristics, and Molecular Associations of IGF1R Mutations in East Asian Patients with NSCLC
Authors: X. Zhao, C. Xu, W. Wang, Q. Zhang, W. Zhuang, Y. Zhu, Y. Huang, G. Chen, M. Fang, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2019)
MA11.03 Pembrolizumab Plus Docetaxel Increases Progression-Free Survival Compared with Docetaxel Alone in Previously Treated Advanced Non-Small Cell Lung Cancer Patients
Authors: O.G. Arrieta, F. Barrón, A. Carmona, L. Ramírez-Tirado, Z.L. Zatarain Barrón, A.F. Cardona, Y. Bautista, F. Aldaco, M. Lazaro, R. Baez, R. Gerson, C. Blanco
Journal: Journal of Thoracic Oncology (2019)
IFN-γ, Unlike TNF-α, LPS, or CD40 Signal, Is Required and Sufficient To Induce Indoleamine 2,3-Dioxygenase Activity in Mesenchymal Stem Cells.
Authors: Karin Tarte, Delphine Monnier, Patricia Ame-Thomas, Joelle Dulong, Céline Bonnaventure, Franck Verite, Thierry Lamy
Journal: Blood (2005)
P2.04-76 Tumor Mutational Burden by TSO500 Next Generation Sequencing Panel and Clinical Outcome in Non-Small Cell Lung Cancer
Authors: K. Cuppens, G. Froyen, B. Cruys, E. Geerdens, R. Achten, M. Vanbockrijck, B. Maes
Journal: Journal of Thoracic Oncology (2019)
P1.04-19 Association Between Efficacy and irAEs in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immune-Checkpoint Inhibitors
Authors: M. Riudavets, J. Mosquera, R. Garcia Campelo, J. Serra, G. Anguera, P. Gallardo, I.G. Sullivan, A. Barba, M. Majem
Journal: Journal of Thoracic Oncology (2019)
A systematic review of source attribution of human campylobacteriosis using multilocus sequence typing
Authors: Alison J Cody, Martin CJ Maiden, Norval JC Strachan, Noel D McCarthy
Journal: Eurosurveillance (2019)

Background Campylobacter is a leading global cause of bacterial gastroenteritis, motivating research to identify sources of human infection. Population genetic studies have been increasingly applied to this end, mainly using multilocus sequence typing (MLST) data. Objectives This review aimed to summarise approaches and findings of these studies and identify best practice lessons for this form of genomic epidemiology. Methods We systematically reviewed publications using MLST data to attribute human disease isolates to source. Publications were from January 2001, when this type of approach began. Searched databases included Scopus, Web of Science and PubMed. Information on samples and isolate datasets used, as well as MLST schemes and attribution algorithms employed, was obtained. Main findings were extracted, as well as any results’ validation with subsequent correction for identified biases. Meta-analysis is not reported given high levels of heterogeneity. Results Of 2,109 studies retrieved worldwide, 25 were included, and poultry, specifically chickens, were identified as principal source of human infection. Ruminants (cattle or sheep) were consistently implicated in a substantial proportion of cases. Data sampling and analytical approaches varied, with five different attribution algorithms used. Validation such as self-attribution of isolates from known sources was reported in five publications. No publication reported adjustment for biases identified by validation. Conclusions Common gaps in validation and adjustment highlight opportunities to generate improved estimates in future genomic attribution studies. The consistency of chicken as the main source of human infection, across high income countries, and despite methodological variations, highlights the public health importance of this source.
P1.01-112 Phase 3, Randomized, Double-Blind Trial of First-Line Pembrolizumab With or Without Lenvatinib in Metastatic NSCLC: LEAP-007
Authors: T. Mekhail, S. Kim, K. Kubota, M. González Del Riego, L. Wu, A. Samkari, T.M. Fouad, J. Chih-Hsin Yang
Journal: Journal of Thoracic Oncology (2019)
구연 : 비알코올성 지방간질환에서 지방간염의 진단 및 간섬유화 정도의 예측인자
Authors: 이동석, 권기태, 조창민, 탁원영, 권영오, 김성국, 최용환, 배한익
Journal: Clinical and Molecular Hepatology (2003)

배경/목적: Ludwig등이 알코올과 관련이 없으면서 알코올성 간염과 동일한 병리학적 변화를 보이는 경우를 비알코올성 지방간염 (NASH: non-alcoholic steatohepatitis)이라 명명한 이후 여러 연구자들에 의해 NASH는 간조직 검사소견상 염증소견이나 섬유화가 없는 비알코올성 지방증(NAS: non-alcoholic steatosis) 과는 달리 간경변으로 진행할 수 있을 뿐만 아니라 간암의 발생과의 연관성에 대한 연구들이 발표되고 있어 최근 NASH의 병태생리나 임상경과, 예후 등에 대해 많은 관심이 모아지고 있다. 특히, 근래에 NASH와 관련이 있는 것으로 알려진 비만환자가 늘어나고 이에 따라 환자 및 의사모두에게 점차 큰 관심영역이 되고 있다. 이에 연구자들은 임상적으로 비알코올성 지방간질환이 의심된 환자들을 대상으로 간조직 검사를 시행하고 조직소견과 임상 자료들을 분석하여 비알코올성 지방증과 지방간염의 상대적인 빈도를 알아보고 양 군의 감별가능한 임상적 인자가 있는지를 확인하고 비알코올성 지방간염에서는 간섬유화 정도를 예측 할 수 있는 인자를 알아보고자 하였다. 대상과 방법: 2000년 1월부터 2003년 3월까지 내원한 환자중, ALT치가 정상의 2배 이상 이면서 간 초음파 또는 복부단층촬영 소견상 지방간 소견을 보이고 알코올이나 약물의 병력이 없고 혈청학적 검사상 바이러스성 간염이 배제되어 비알코올성 지방간질환이 의심된 환자 41명을 대상으로 하여 간조직 검사를 시행하였다. 조직검사 결과를 지방증과 지방간염군으로 나누어 두 군에서 혈청학적 검사 및 체질량지수 (body mass index, BMI), 간초음파 소견 등을 비교하였으며, 지방간염에서는 간섬유화 정도를 예측 할 수 있는 관련 인자들이 있는지를 조사하였다. 결과: 1) 간조직검사상 지방증은 11예 (26.8%) 지방간염은 30예 (73.2%) 이었고, 평균연령은 각각 33.3세, 27.3세, 남녀 성비는 7:4, 26:4로서 의미 있는 차이는 없었다. 2) 지방증군과 지방간염군의 비교에서는 BMI, 혈청검사, 간초음파소견상 지방간의 정도 등을 비교한 결과 BMI가 유일하게 의미 있는 차이를 보였다 (지방증:25.4 지방간염:28.7 p＝0.005) 3) ROC curve를 이용한 cut-off 치로 BMI 27.2 이상이면 NASH의 진단 가능성이 매우 높았다(민감도:70%, 특이도: 91%) 4) NASH 군에서는 7%만이 간섬유화가 없었고, 40%는 중등도 이상의 간섬유화를 보였으나 간경변은 없었다. 5) NASH의 간섬유화 정도를 반영하는 임상지표로는 높은 BMI (p＝0.011)가 심한 간섬유화와 관계되었다. 결론: 임상적으로 비알코올성 지방 간질환으로 의심되는 경우 간조직 검사상 지방간염의 비율이 높고 (특히 BMI 27이상), 지방간염에서 섬유화의 정도는 BMI와 상관관계가 높은 것으로 확인되어 정확한 조직학적 진단과 향후 예후 판단 및 비만치료의 동기 유발 등의 목적으로 적극적인 간조직 검사가 필요할 것으로 생각된다.
P2.12-13 Lurbinectedin (L) Combined with Paclitaxel (P) or Irinotecan (I) in Relapsed SCLC. Results from Two Phase Lb Trials
Authors: S. Ponce, E. Calvo, M.J. De Miguel, C. Sessa, M.J. Flor, A. Drilon, A. Falcon, I. Sanchez Simon, R. Nuñez, X.E. Luepke, N. Cuevas-Melendez, J. López-Vilariño, S. Fudio, M. Siguero, M. Cullell-Young, C. Kahatt, A. Zeaiter, L. Paz-Ares
Journal: Journal of Thoracic Oncology (2019)
EP1.12-21 Treatment Patterns and Prognostic Factors in Small-Cell Lung Cancer Patients in Israel – Real World Analysis of a Health Services Database
Authors: S. Sharman Moser, J. Bar, I. Khan, K. Ofek, R. Cohen, N. Khandelwal, V. Shalev, G. Chodick, N. Siegelmann-Danieli
Journal: Journal of Thoracic Oncology (2019)
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial
Authors: Yeon Hee Park, Tae-Yong Kim, Gun Min Kim, Seok Yun Kang, In Hae Park, Jee Hyun Kim, Kyoung Eun Lee, Hee Kyung Ahn, Moon Hee Lee, Hee-Jun Kim, Han Jo Kim, Jong In Lee, Su-Jin Koh, Ji-Yeon Kim, Kyung-Hun Lee, Joohyuk Sohn, Sung-Bae Kim, Jin-Seok Ahn, Young-Hyuck Im, Kyung Hae Jung, Seock-Ah Im, HK Ahn, EK Cho, IH Park, KS Lee, SS Sim, SJ Hong, MH Chang, JH Kim, YJ Kim, SH Kim, KJ Suh, YH Park, WY Park, YL Choi, JH Yu, YH Im, JS Ahn, JY Hur, SH Park, JY Kim, SJ Nam, JE Lee, SW Kim, SK Lee, SA Im, MS Kim, TY Kim, DY Oh, TY Kim, KH Lee, DW Lee, HJ Kim, KH Jung, SB Kim, JH Ahn, JE Kim, JH Jung, SY Kang, MS Ahn, YW Choi, GM Kim, JH Sohn, MH Kim, SJ Koh, JK Cheon, JI Lee, ST Lim, SY Hyun, KE Lee, HJ Kim, MH Lee, JH Cho, JH Lim
Journal: The Lancet Oncology (2019)
P2.16-32 Best Supportive Care for Extreme Elderly Lung Cancer Patients
Authors: T. Kazuyori, Y. Seki, A. Sato, S. Fujimoto, M. Yamada, Y. Yamanaka, I. Fujisaki, K. Odashima, A. Seki, T. Ishikawa, K. Kuwano
Journal: Journal of Thoracic Oncology (2019)
NARD: whole-genome reference panel of 1779 Northeast Asians improves imputation accuracy of rare and low-frequency variants
Authors: Seong-Keun Yoo, Chang-Uk Kim, Hie Lim Kim, Sungjae Kim, Jong-Yeon Shin, Namcheol Kim, Joshua Sung Woo Yang, Kwok-Wai Lo, Belong Cho, Fumihiko Matsuda, Stephan C. Schuster, Changhoon Kim, Jong-Il Kim, Jeong-Sun Seo
Journal: Genome Medicine (2019)

Here, we present the Northeast Asian Reference Database (NARD), including whole-genome sequencing data of 1779 individuals from Korea, Mongolia, Japan, China, and Hong Kong. NARD provides the genetic diversity of Korean (n = 850) and Mongolian (n = 384) ancestries that were not present in the 1000 Genomes Project Phase 3 (1KGP3). We combined and re-phased the genotypes from NARD and 1KGP3 to construct a union set of haplotypes. This approach established a robust imputation reference panel for Northeast Asians, which yields the greatest imputation accuracy of rare and low-frequency variants compared with the existing panels. NARD imputation panel is available at https://nard.macrogen.com/ .
EP1.14-47 Lung Adenocarcinoma with Concurrent KRAS Mutation and ALK Rearrangement Responding to Crizotinib
Authors: Y. Zhu, W. Wang, C. Xu, X. Li, W. Zhuang, K. Du, G. Chen, M. Fang, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2019)
P2.17-09 Preoperative Risk Factors of Potential Failure for Lobe-Specific Nodal Dissection in Clinical Early Stage (I-IIA) Non-Small Cell Lung Cancer
Authors: Y. Chong, J.K. Yun, Y.H. Jeong, G.D. Lee, S. Choi, H.R. Kim, Y. Kim, S. Park, D.K. Kim
Journal: Journal of Thoracic Oncology (2019)
Myeloid Cell Differentiation Arrest by Mir-125b-1 in Myelodysplasic Syndrome and Acute Myeloid Leukemia with the T(2;11)(p21;q23) Translocation
Authors: Marina Bousquet, Cathy Quelen, Roberto Rosati, Véronique Mansat-De Mas, Christian Bastard, Eric Lippert, Pascaline Talmant, Marina Lafage-Pochitaloff, Dominique Leroux, Carine Gervais, Franck Viguie, Jean-Luc Lai, Christine Terre, Georges Delsol, Nicole Dastugue, Cristina Mecucci, Pierre Brousset
Journal: Blood (2008)
P2.01-33 Survival Benefit of Depleting High Serum EGF Concentration in Advanced NSCLC Patients as Switch Maintenance Therapy
Authors: O. Santos Morales, E. Neninger, R. Carrodeguas, P. Luaces, P. Rodríguez, M. Hernandez, C. González, T. Crombet
Journal: Journal of Thoracic Oncology (2019)
MA10.09 Evaluation of the Clinical Utility of the PanCan, EU-NELSON and Lung-RADS Protocols for Management of Screen Detected Lung Nodules at Baseline
Authors: R. Myers, J. Mayo, M. Tammemägi, S. Atkar-Khattra, R. Yuan, J. Yee, J. English, K. Grant, A. Lee, A. Mcguire, A. Mcwilliams, F. Brims, L. Mo, S. Lam
Journal: Journal of Thoracic Oncology (2019)
The Mask Sign—An Imaging Marker of Traumatic Spinal Cord Hemorrhage
Authors: Jacqueline C. Junn, Jason Talbott, Jared Narvid
Journal: JAMA Neurology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Phase I study of peptide vaccine targeting indeolamine 2,3 dioxygenase in metastatic lung cancer patients.
Authors: Trine Zeeberg Iversen, Lotte Engell-Noerregaard, Eva Ellebaek, Rikke Andersen, Stine Kiaer Larsen, Jon Bjoern, Merete Jonassen, Hubert Kalbacher, Claus Zeyher, Cecile Gouttefangeas, Inger Birthe Moerk Thomsen, Bente Holm, Anders Mellemgaard, Per thor Straten, Mads Hald Andersen, Inge Marie Svane
Journal: Journal of Clinical Oncology (2013)

8084 Background: To investigate the targeting of indeolamine 2,3 dioxygenase (IDO) enzyme by a synthetic peptide vaccine for patients with metastatic non small-cell lung cancer (NSCLC). Methods: We treated15 HLA-A2 positive patients with stage III-IV NSCLC and disease stabilization (SD) after standard chemotherapy. Patients were treated every second week (induction) for three months, and thereafter monthly until progression (maintenance) with imiquimod ointment and vaccine (100 µg IDO5 peptide sequence ALLEIASCL mixed with 900 µL montanide) administered subcutaneously. Primary end point was toxicity. Clinical benefit and immune monitoring were assessed. Results: Patient characteristics: mean age (63, range 51-71), sex (F=8,M=7), PS(0=9,1=6), histology (adenocarcinoma=93%), previously anti-neoplastic treatments (1 st line=100%, 2 nd =40% and 3 rd =27% of patients). No grade 3-4 CTCAE toxicity was observed. Median PFS was 5.2 months and median OS 2.1 years. Long-lasting disease stabilization (SD≥8.5 months) was demonstrated in 7 patients (47%). Patients demonstrated significant improved OS (P=0.02) when compared to the untreated group of excluded HLA-A2 negative NSCLC patients. IDO expression was frequently detected in tumour biopsies by immune-histochemistry staining. Immune induction of IDO specific CD8 T-cells were demonstrated by IFN-y Elispot and Tetramer staining. Immune correlates of T-lymphocyte subsets were performed by flow cytometry. HPLC analyses of Trp/Kyn ratio suggested stabilization or decrease of IDO activity in 11/15 (73%) of the patients. Conclusions: The vaccine was safe and well-tolerated with no grade 3/4 toxicity occurring. Long-lasting SD was seen in 47% of the patients demonstrating a median OS of 2.1 year. IHC demonstrated frequent IDO activity in NSCLC tumour biopsies, and blocking of IDO activity was indicated by Kyn/Trp ratio measurements. Clinical trial information: NCT01219348.
A rare case of aberrant pancreas in the colon: choristoma of Bauhin’s valve
Authors: Pavel V. Pavlov, Andrey P. Kiryukhin, Alexander S. Tertychnyi, Yuri E. Kitsenko
Journal: Endoscopy (2019)

A 48-year-old man with normal antenatal history was admitted to hospital with complaints of recurrent nonintensive pain on the right side. The patient had a medical history of Crohn’s disease (remission) for the past 5 years.